moskene: causes allergic photocontact dermatitis; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 67005 |
CHEMBL ID | 3188408 |
SCHEMBL ID | 651789 |
MeSH ID | M0126304 |
Synonym |
---|
indan, 1,1,3,3,5-pentamethyl-4,6-dinitro- |
nsc 60035 |
einecs 204-149-4 |
musk moskene |
brn 2163411 |
indan, 4,6-dinitro-1,1,3,3,5-pentamethyl- |
ai3-28025 |
1h-indene, 2,3-dihydro-1,1,3,3,5-pentamethyl-4,6-dinitro- |
1,1,3,3,5-pentamethyl-4,6-dinitrolindan |
4,6-dinitro-1,1,3,3,5-pentamethylindan |
ccris 7622 |
1,1,3,3,5-pentamethyl-4,6-dinitroindane |
1,1,3,3,5-pentamethyl-4,6-dinitroindan |
nsc60035 |
indan,1,3,3,5-pentamethyl-4,6-dinitro- |
1,3,3,5-pentamethyl-4,6-dinitroindan |
moskene |
1,3,3,5-pentamethyl-4,6-dinitrolindan |
116-66-5 |
1h-indene,3-dihydro-1,1,3,3,5-pentamethyl-4,6-dinitro- |
nsc-60035 |
OPREA1_114805 |
SR-01000640158-1 |
MAYBRIDGE1_007103 |
HMS561K19 |
1,1,3,3,5-pentamethyl-4,6-dinitro-2h-indene |
musk moskine |
1q49ic9faw , |
unii-1q49ic9faw |
4-05-00-01463 (beilstein handbook reference) |
dtxcid4024519 |
NCGC00255930-01 |
1,1,3,3,5-pentamethyl-4,6-dinitro-2,3-dihydro-1h-indene |
cas-116-66-5 |
dtxsid6044519 , |
tox21_302237 |
AKOS024319064 |
CCG-50813 |
BP-10214 |
FT-0629038 |
4,6-dinitro-1,1,3,3,5-pentamethylindane |
SCHEMBL651789 |
UHWURQRPEIFIAK-UHFFFAOYSA-N |
CHEMBL3188408 |
J-003468 |
musk moskene 10 microg/ml in cyclohexane |
CS-0204281 |
1,1,3,3,5-pentamethyl-4,6-dinitro-indan |
Q27252741 |
BS-19261 |
Musk moskene is a soft, sweet fragrance resembling musk ambrette. It introduces a very desirable creamy powder note for cosmetic fragrance.
Excerpt | Reference | Relevance |
---|---|---|
"Musk moskene is a soft, sweet fragrance resembling musk ambrette which introduces a very desirable creamy powder note for cosmetic fragrance. " | ( Pigmented contact dermatitis due to musk moskene. Arima, Y; Hayakawa, R; Hirose, O, 1991) | 1.06 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 4.7184 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
SMAD family member 2 | Homo sapiens (human) | Potency | 9.7700 | 0.1737 | 34.3047 | 61.8120 | AID1346924 |
SMAD family member 3 | Homo sapiens (human) | Potency | 9.7700 | 0.1737 | 34.3047 | 61.8120 | AID1346924 |
AR protein | Homo sapiens (human) | Potency | 13.7460 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID743042; AID743054 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 7.3244 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
progesterone receptor | Homo sapiens (human) | Potency | 17.2289 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 20.3161 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 29.2588 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 54.9410 | 0.3758 | 27.4851 | 61.6524 | AID743217 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 54.4827 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 21.2558 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID743075; AID743077; AID743080; AID743091 |
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 27.3060 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 42.1394 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1224895 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 64.8601 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 61.1306 | 0.0006 | 27.2152 | 1,122.0200 | AID743202 |
Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 30.6379 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 1.3685 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 30.6379 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 24.3365 | 0.0119 | 17.9420 | 71.5630 | AID651632 |
Ataxin-2 | Homo sapiens (human) | Potency | 24.3365 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (5.56) | 18.7374 |
1990's | 7 (38.89) | 18.2507 |
2000's | 3 (16.67) | 29.6817 |
2010's | 6 (33.33) | 24.3611 |
2020's | 1 (5.56) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (70.42) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 2 (11.11%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 16 (88.89%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |